The Hugh Kaul Precision Medicine Institute (PMI) works with individuals, families, researchers, patient foundations, and clinicians to use artifical intelligence (AI) to research therapeutic strategies to treat genetic disorders including rare disease.

We use data science, bioinformatics, artificial intelligence, and consultation with experts to develop therapeutics strategies to treat genetic disorders including rare disease, cancer, and diabetes. Our experts have developed a logic-driven computer language, known as mediKanren, to access large data sets (PubMed, UniProt, etc.) in order to utilize information in a relationship-based manner, allowing us to quickly link together drugs to genes, or genes to disease.

Our research consultation study is designed for individuals and families living with a rare genetic disorder. Each case will be paired with one of our dedicated student analysts.

• Our process begins with a genetics report and a review of the published research relevant to the gene, variant, and/or disorder. We also review any ongoing research and clinical trials.

• We then develop a hypothesis regarding the predicted impact of the genetic variant, which guides research into treatment strategies.

• Lastly, our AI tools help identify innovative treatment or research avenues for drug repurposing.

Researchers and patient foundations can also reach out to us separately to collaborate on an AI-driven drug repurposing list.

If you are interested in joining our research consultation study or would like to collaborate on an AI-driven drug repurposing list, please email pmianalysts@uab.edu.